1) La descarga del recurso depende de la página de origen
2) Para poder descargar el recurso, es necesario ser usuario registrado en Universia


Opción 1: Descargar recurso

Opción 2: Descargar recurso

Detalles del recurso

Descripción

Background Preclinical results showing therapeutic effect and low toxicity of metronomic chemotherapy with cyclophosphamide (Cy) + celecoxib (Cel) for mammary tumors encouraged its translation to the clinic for treating advanced breast cancer patients (ABCP). Patients and methods A single-arm, mono-institutional, non-randomized, phase II, two-step clinical trial (approved by Bioethics Committee and Argentine Regulatory Authority) was designed. Patients received Cy (50 mg po.d) + Cel (200 mg p.o.bid). Patient eligibility criteria included: ABCP who progressed to anthracyclines, taxanes and capecitabine, ≤4 chemotherapy schemes, with good performance status. Several pro- and anti-angiogenic molecules and cells were determined as biomarkers. Informed consent was signed by all patients. Primary endpoint was clinical benefit (CB). Results Twenty patients were enrolled. Main clinical outcomes were prolonged disease stabilization and partial remission in 10/20 and 1/20 patients, respectively. CB was 55 %, and time to progression (TTP) was 21.1 weeks. Median TTP in patients who achieved CB was 35.6 weeks, and mean overall survival was 44.20 weeks. There were no grade 3/4 toxicities associated with treatment. Circulating endothelial cells (CECs) increased at the time of progression in patients who showed CB (P = 0.014). Baseline CECs and circulating endothelial progenitor cells showed marginal associations with TTP. Serum VEGF decreased (P = 0.050), sVEGFR-2 increased (P = 0.005) and VEGF/sVEGFR-2 ratio decreased during treatment (P = 0.041); baseline VEGF and VEGF/sVEGFR-2 were associated with TTP (P = 0.035 and P = 0.030, respectively), while sVEGFR-2 did not. Conclusions Treatment was effective, showing low toxicity profile and excellent tolerability. The combination had anti-angiogenic effect. Increased levels of CEC could be useful for detecting progression. Baseline VEGF and VEGF/sVEGFR-2 values could be useful as early predictors of response. Trial registration ANMAT#4596/09.

Pertenece a

Repositorio Hipermedial UNR - Repositorio Hipermedial de la Universidad Nacional de Rosario  

Autor(es)

Perroud, Herman A -  Alasino, Carlos María  -  Rico, María José -  Mainetti, Leandro Ernesto -  Queralt, Francisco  -  Pezzotto, Stella Maris -  Rozados, Viviana R. -  Scharovsky, O. Graciela - 

Id.: 71216644

Idioma: eng  - 

Versión: 1.0

Estado: Final

Tipo:  application/pdf - 

Palabras claveAngiogenesis  - 

Tipo de recurso: article  -  artículo  -  acceptedVersion  - 

Tipo de Interactividad: Expositivo

Nivel de Interactividad: muy bajo

Audiencia: Estudiante  -  Profesor  -  Autor  - 

Estructura: Atomic

Coste: no

Copyright: sí

: Springer

Formatos:  application/pdf - 

Requerimientos técnicos:  Browser: Any - 

Relación: [References] https://doi.org/10.1007/s00280-015-2947-9

Fecha de contribución: 14-abr-2018

Contacto:

Localización:
* 1432-0843

Otros recursos del mismo autor(es)

  1. Clinical response in patients with ovarian cancer treated with metronomic chemotherapy Ovarian cancer (OC) is the leading cause of death from gynaecological cancer. It is extremely hard t...
  2. A mammary adenocarcinoma murine model suitable for the study of cancer immunoediting La inmunoedición del cáncer es un proceso dinámico compuesto de tres fases: eliminación (EL), equili...
  3. Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models Discovery of new drugs for cancer treatment is an expensive and time-consuming process and the perce...
  4. Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients Metronomic chemotherapy (MCT), the chronic administration, at regular intervals, of low doses of che...
  5. Comparative Effectiveness of Two Metronomic Chemotherapy Schedules. Our Experience in the Preclinical Field Metronomic chemotherapy refers to the chronic, equally spaced, delivery of low doses of chemotherape...

Otros recursos de la mismacolección

  1. Clinical response in patients with ovarian cancer treated with metronomic chemotherapy Ovarian cancer (OC) is the leading cause of death from gynaecological cancer. It is extremely hard t...
  2. A mammary adenocarcinoma murine model suitable for the study of cancer immunoediting La inmunoedición del cáncer es un proceso dinámico compuesto de tres fases: eliminación (EL), equili...
  3. Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models Discovery of new drugs for cancer treatment is an expensive and time-consuming process and the perce...
  4. Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients Metronomic chemotherapy (MCT), the chronic administration, at regular intervals, of low doses of che...
  5. Comparative Effectiveness of Two Metronomic Chemotherapy Schedules. Our Experience in the Preclinical Field Metronomic chemotherapy refers to the chronic, equally spaced, delivery of low doses of chemotherape...

Aviso de cookies: Usamos cookies propias y de terceros para mejorar nuestros servicios, para análisis estadístico y para mostrarle publicidad. Si continua navegando consideramos que acepta su uso en los términos establecidos en la Política de cookies.